Patents by Inventor Robert A. Kirken

Robert A. Kirken has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180256715
    Abstract: Embodiments are directed to therapeutic antibodies or antibody fragments that relieve suppression of the immune system, as well therapeutic methods using the same.
    Type: Application
    Filed: May 13, 2016
    Publication date: September 13, 2018
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Robert Kirken, Georgialina Rodriguez
  • Patent number: 7928062
    Abstract: Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e.g., T-cells, B-cells). A Mannich base compound, or a derivative or modified compound, is employed which is capable of selectively inhibiting Jak3 while affecting other protein tyrosine kinase activities to a lesser extent or not at all, to provide beneficial effects such as mitigation of transplant rejection and alleviation of allergic responses with fewer side effects than with conventional immunosuppressive agents.
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: April 19, 2011
    Assignee: Board of Regents of the University of Texas System
    Inventors: Robert A. Kirken, Barry D. Kahan, Stanislaw M. Stepkowski, Waldemar Priebe, Izabela Fokt, Szymon Kosinski
  • Publication number: 20100086442
    Abstract: The present invention provides a sensor for the detection of chemical agents in real time. The sensor includes a sample region having a detector disposed about a substrate where a chemical agent binds to the detector to generate in a signal. The sensor includes a microcontroller in communication with the detector, an analog to digital converter, and a communication module to process the signal into an analytical signal. In addition, the sensor includes an antenna in communication with the microcontroller to enable a wireless communication network, wherein the analytical signal can be transmitted and a power source in operable communication with the microcontroller to supply a source of power to the sensor.
    Type: Application
    Filed: October 3, 2009
    Publication date: April 8, 2010
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Robert Kirken, Eric MacDonald, Ryan Wicker, Kristin Gosselink
  • Publication number: 20080167220
    Abstract: Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e.g., T-cells, B-cells). A Mannich base compound, or a derivative or modified compound, is employed which is capable of selectively inhibiting Jak3 while affecting other protein tyrosine kinase activities to a lesser extent or not at all, to provide beneficial effects such as mitigation of transplant rejection and alleviation of allergic responses with fewer side effects than with conventional immunosuppressive agents.
    Type: Application
    Filed: November 5, 2007
    Publication date: July 10, 2008
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Robert A. KIRKEN, Barry D. KAHAN, Stanislaw M. STEPKOWSKI, Waldemar PRIEBE, Izabela FOKT, Szymon KOSINSKI
  • Patent number: 7365096
    Abstract: Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e.g., T-cells, B-cells). A Mannich base compound, or a derivative or modified compound, is employed which is capable of selectively inhibiting Jak3 while affecting other protein tyrosine kinase activities to a lesser extent or not at all, to provide beneficial effects such as mitigation of transplant rejection and alleviation of allergic responses with fewer side effects than with conventional immunosuppressive agents.
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: April 29, 2008
    Assignee: Board of Regents, The University of Texas System
    Inventors: Robert A. Kirken, Barry D. Kahan, Stanislaw M. Stepkowski, Waldemar Priebe, Izabela Fokt, Szymon Kosinski
  • Publication number: 20050203177
    Abstract: Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e.g., T-cells, B-cells). A Mannich base compound, or a derivative or modified compound, is employed which is capable of selectively inhibiting Jak3 while affecting other protein tyrosine kinase activities to a lesser extent or not at all, to provide beneficial effects such as mitigation of transplant rejection and alleviation of allergic responses with fewer side effects than with conventional immunosuppressive agents.
    Type: Application
    Filed: December 9, 2003
    Publication date: September 15, 2005
    Applicant: Board of Regents,The University of Texas System
    Inventors: Robert Kirken, Barry Kahan, Stanislaw Stepkowski, Waldemar Priebe, Izabela Fokt, Szymon Kosinski